|
Avivagen Inc. (TSX-V: VIV) , a company with a commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, intends to effect a 10 to 1 consolidation of its common shares. The date on which the Consolidation will take effect will be announced once the TSX Venture Exchange approval has been received. The Consolidation was approved by the Corporation's shareholders at the annual general and special meeting of shareholders held on April 11, 2017. "We heard from a number of institutional investors and potential purchasers of our OxC-betaTM for Livestock product that we had the right operating company profile, but didn't fit the appropriate capital markets profile in order for them to do business with us. As we consider international expansion and U.S. capital markets strategies, we considered a consolidation factor of 10 to 20 old shares for each new share. Based on our view of our growth potential, we have unanimously selected the 10:1 ratio. We will provide another press release the day before the share consolidation will take effect." - Kym Anthony, Chairman and Interim CEO of Avivagen Inc. Last month, Avivagen announced positive results from a proof-of-concept study that could extend Avivagen’s OxC-beta™ technology into human health applications. The proof-of-concept study evaluated Avivagen’s OxC-beta™ technology as a preventative therapeutic against C. difficile infection (CDI). As strains of C. difficile change, antibiotics are becoming less effective or even completely ineffective in clearing CDI. The proof-of-concept study evaluated three doses of the OxC-beta™ technology for the ability to improve survival rate, increase median time until death, and improve clinical indicators of health using a standard mouse model of human C. difficile infection. The results of the study demonstrate that the highest dose of the OxC-beta™ technology tested increased survivability and clinical scores in mice compared to the un-supplemented mouse control group. Treatment with the OxC-beta™ technology increased median time until death to greater than seven days in the mouse group treated with OxC-beta compared to only three days in the un-supplemented mouse control group. About OxC-beta™ Livestock There is growing pressure on food producers to maintain high production and low costs, while continuing to bring us great tasting, high quality food. Historically, the use of antibiotics at low doses to help optimize the growth of food animals has helped to achieve this aim. Avivagen has developed a proprietary, naturally-derived product, OxC-beta™, which has been clinically proven to help animals grow healthier, faster, with comparable feed rations, reducing the single-largest cost in rearing food animals.
0 Comments
Avivagen Inc. (TSX-V: VIV, OTC Pink: CHEXF), a Corporation with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announced at the Corporation's annual and special meeting of shareholders (AGM) held yesterday that the shareholders voted to support the resolutions proposed by the Corporation. The resolutions and the voting results included the following:
The Corporation is pleased to have Mr. Jeffrey Kraws join the Board of Directors. Mr. Kraws is a co-founder and Chief Executive Officer of Crystal Research Associates, a firm established in 2003 in response to the growing need for independent equity research and innovative thinking in today's highly competitive markets. Mr. Kraws has received some of the most prestigious awards in the industry, including being consistently ranked among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates by Zacks. Additionally, Mr. Kraws has been 5-Star-ranked for top biotechnology stock performance by Starmine. Mr. Kraws is currently chairman of Synthetic Biologics Inc., a NYSE-listed biotechnology company, and a partner and co-founder of TopHat Capital, LLC. He is also the President of Ra Medical, a medical device company commercializing breakthrough laser therapies for a number of dermatology and vascular diseases. He also serves as a director of Saleen Automotive. Through his years of experience, Mr. Kraws has cultivated a wealth of industry knowledge and a level of credible, insightful equity analysis that few share. As a result, he has provided guest commentary for many network news programs, including Bloomberg, FOX Business, and CNBC, among others, and has become a valuable resource for financial journalists from the New York Times, Forbes, Bloomberg, CBS MarketWatch, and MedAdNews, among other publications. Mr. Kraws holds an MBA from Cornell University and a B.S. from the State University of New York-Buffalo. Avivagen Remains Focused on Gaining Market Approval of OxC-beta™ in Multiple Geographies At the AGM, the Chair of the Board of Directors and Interim CEO, Mr. Kym Anthony, indicated that the Corporation was continuing to pursue the following key initiatives:
About Avivagen Avivagen Inc. is a public company traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com .  Avivagen Inc. (TSX-V: VIV) (OTC Pink: CHEXF) announced positive results from a proof-of-concept study that could extend Avivagen’s OxC-beta™ technology into human health applications. The proof-of-concept study evaluated Avivagen’s OxC-beta™ technology as a preventative therapeutic against C. difficile infection (CDI). As strains of C. difficile change, antibiotics are becoming less effective or even completely ineffective in clearing CDI. It is estimated that CDI adds an annual economic burden of US$1.5 billion to the United States healthcare system.
The proof-of-concept study evaluated three doses of the OxC-beta™ technology for the ability to improve survival rate, increase median time until death, and improve clinical indicators of health using a standard mouse model of human C. difficile infection. The research was conducted by the National Research Council of Canada (NRC), the Government of Canada’s premier research organization supporting industrial innovation, the advancement of knowledge, technology development, and fulfilling government mandates. The results of the study demonstrate that the highest dose of the OxC-beta™ technology tested increased survivability and clinical scores in mice compared to the un-supplemented mouse control group. Treatment with the OxC-beta™ technology increased median time until death to greater than seven days in the mouse group treated with OxC-beta compared to only three days in the un-supplemented mouse control group. About Avivagen Avivagen Inc. is a public company traded on the TSX-V under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. |
Archives
November 2020
Categories
All
|
RSS Feed